2023.11.29IR

Notice on the progress of domestic Phase II clinical trials of NF-κB decoy oligo DNA for the treatment of chronic intervertebral disc low back pain

2023.11.15IR

Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB of the AV-001 Phase 2a Study

2023.11.08IR

Consolidated Financial Report for the Third Quater 2023

2023.10.18IR

Notice Regarding the Start of Administration of NF-κB Decoy Oligo DNA for the Treatment of Chronic Intervertebral Disc Lumbago in a Phase II Clinical Trial in Japan

2023.08.09IR

Consolidated Financial Report for the Second Quater 2023

Learn more